Weight-loss drugs

Weight-loss drugs now account for 8 to 9 percent of revenue at Brazil’s largest pharmacy groups, with Pague Menos reporting 9.1 percent sales share in early 2026, a 167 percent annual increase.

Canada is the first G7 country to approve lower cost generic Ozempic for weight loss, with the drugs beginning to roll out in pharmacies this month.

Taking weight-loss drugs for at least three years may reduce the risk of knee replacements for patients with knee arthritis, according to a study. Globally, over 500 million people have osteoarthritis, with 14 million in the US and 5 million in the UK affected by knee arthritis. Over 120,000 knee replacements are performed annually in the UK.

Weight-loss drugs may be altering the brain to reduce cravings for food, alcohol, and sex, according to a study. The research suggests these medications could dampen desire for multiple pleasures beyond weight loss.

Weight-loss drugs may reshape the brain to reduce people's desire for food, alcohol, and sex, according to a study. The findings suggest these drugs could alter neural responses to such stimuli.

France will partially reimburse weight-loss drugs like Wegovy for obesity patients, aiming to improve access and health outcomes. The article mentions Wegovy's availability at New City Halstead Pharmacy in Chicago, Illinois.

A new weight-loss drug called Retatrutide is showing promising trial results that exceed the effectiveness of current weight-loss medications available on the market. Although not yet approved for public use, the drug demonstrates significantly stronger outcomes than existing options. Dr. Jon LaPook provides expert analysis on the drug's potential.

Eli Lilly announced that its new weight-loss drug retatrutide significantly outperforms existing obesity medications, with trial participants losing an average of 28.3% of body weight over 80 weeks. The once-weekly injection led to 45.3% of participants achieving at least 30% weight loss, representing a major advancement in obesity treatment.

The active ingredient in Ozempic, a popular weight-loss drug, may help reduce alcohol use in individuals with obesity, according to a new study. The findings suggest potential for treating alcohol use disorder alongside obesity.